China SXT Pharmaceuticals (SXTC) Operating Leases (2023 - 2025)

China SXT Pharmaceuticals' Operating Leases history runs 3 years deep, the most recent figure standing at $85161.0 for Q3 2025.

• In Q3 2025, Operating Leases fell 53.38% year-over-year to $85161.0; the TTM figure through Sep 2025 stood at $85161.0 (down 53.38% YoY), while the FY2025 annual figure was $115419.0, down 51.06% from the prior year.
• Operating Leases was $85161.0 for Q3 2025 at China SXT Pharmaceuticals, down from $115419.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $306050.0 in Q1 2023 to a low of $85161.0 in Q3 2025.
• Historically, Operating Leases has averaged $188347.0 across 3 years, with a median of $193802.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Leases declined 10.87% in 2024, then slumped 53.38% in 2025.
• A 3-year view of Operating Leases shows it stood at $204937.0 in 2023, then slipped by 10.87% to $182667.0 in 2024, then plunged by 53.38% to $85161.0 in 2025.
• The last three Operating Leases figures came in at $85161.0 (Q3 2025), $115419.0 (Q1 2025), and $182667.0 (Q3 2024), per Business Quant data.